nmsg

Nerviano Medical Sciences to present a novel orally available selective small molecule Cdc7 inhibitor at the AACR Annual Meeting 2014

Nerviano, Feb 25, 2014. – Nerviano Medical Sciences will disclose data on a novel orally available selective small molecule Cdc7 inhibitor at the AACR Annual Meeting 2014.

NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer. Montagnoli, A et al.

 

Abstract number: 4539/25. Presentation time: Tue, Apr 08, 1:00 - 5:00 PM

 

Further details will be disclosed when abstract bodies will be made available on the conference website, at the following link.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Per offrirti un'esperienza di navigazione ottimizzata NMS Group e le società controllate utilizzano cookies, anche di terze parti.
Proseguendo con la navigazione acconsenti al loro impiego in conformità della nostra  
Cookie Policy.